XHKG
6118
Market cap64mUSD
Dec 05, Last price
0.98HKD
1D
1.03%
1Q
-19.01%
Jan 2017
-15.52%
IPO
-70.39%
Name
Austar Lifesciences Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||